ReFlow Medical, Inc. today announced that it has signed an exclusive distribution and sales agreement for ReFlow’s suite of peripheral chronic total occlusion (CTO) products with MicroPort Endovascular (MicroPort Endo), a division of MicroPort Scientific Corporation (MicroPort), a leading medical device company in China.
ReFlow has developed a suite of products to cost-effectively address unmet needs in the CTO market. ReFlow’s Wingman crossing catheter is 510(k) cleared and CE Marked to be used in conjunction with steerable guidewires to access discrete regions of the peripheral vasculature and enable rapid, routine, off-the-shelf lesion crossing. The Wingman is the first of several new product families to address the clinical challenges of the CTO market that ReFlow plans to introduce around the world.
“MicroPort’s successful history of obtaining timely regulatory approvals, launching new products, and rapidly expanding market share makes it an ideal partner for us in China,” Isa Rizk, President and CEO of ReFlow, said. “We look forward to working with MicroPort to develop this important market and to drive market adoption of ReFlow’s products.”
Zhonghua Li, Executive Vice General Manager of MicroPort Endo, commented that, “We are very pleased to have entered into this long-term distribution agreement with ReFlow. ReFlow’s products provide a unique solution to addressing the growing CTO opportunity in China with a cost-effective, and easy-to-use solution.”
“We are very pleased to have entered into this long-term distribution agreement with ReFlow. ReFlow’s products provide a unique solution to addressing the growing CTO opportunity in China with a cost-effective, and easy-to-use solution.”